161.00 -0.56 (-0.35%)
Before hours: 4:05AM EST
Previous Close | 160.96 |
Open | 161.43 |
Bid | 157.27 x 900 |
Ask | 165.29 x 800 |
Day's Range | 159.62 - 162.10 |
52 Week Range | 90.14 - 176.64 |
Volume | 2,516,495 |
Avg. Volume | 1,721,158 |
Market Cap | 76.784B |
Beta (5Y Monthly) | 0.68 |
PE Ratio (TTM) | 46.56 |
EPS (TTM) | 3.47 |
Earnings Date | Feb 16, 2021 |
Forward Dividend & Yield | 1.00 (0.62%) |
Ex-Dividend Date | Jan 19, 2021 |
1y Target Est | 185.00 |
For his second "Executive Decision" segment of Wednesday night's Mad Money program, Jim Cramer spoke with Kristin Peck, CEO of Zoetis , the drug maker specializing in pets. Peck explained that with the pandemic, pet adoption has risen by 15%, and with so many people spending more time with their pets, they're noticing their pets' medical needs more than ever. Zoetis has over 200 product lines across eight species.
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Zoetis will report Q4 and full year 2020 financial results on Tuesday, Feb 16, 2021.